Literature DB >> 24415970

How long will I be blue? Prolonged skin staining following sentinel lymph node biopsy using intradermal patent blue dye.

Metehan Gumus1, Hatice Gumus2, Sue E Jones3, Peter A Jones3, Ali R Sever4, Jennifer Weeks4.   

Abstract

BACKGROUND: Blue dye used for sentinel lymph node biopsy (SLNB) in breast cancer patients may cause prolonged skin discoloration at the site of injection. The aim of this study was to assess the duration of such skin discoloration. PATIENTS AND METHODS: 236 consecutive patients who had undergone breast conserving surgery and SLNB for breast cancer were reviewed prospectively from January 2007 to December 2009.
RESULTS: Of the 236 patients, 2 had undergone bilateral surgery, and 41 had been examined in consecutive yearly reviews. Blue discoloration remained visible at the injection site after 12, 24, and > 36 months in 36.5, 23.6, and 8.6% of the patients, respectively.
CONCLUSION: The use of patent blue for identification of the sentinel lymph node in patients undergoing breast cancer surgery may result in prolonged discoloration of the skin at the injection site.

Entities:  

Keywords:  Axillary staging; Patent blue; Sentinel lymph node biopsy; Skin discoloration

Year:  2013        PMID: 24415970      PMCID: PMC3728719          DOI: 10.1159/000352092

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  19 in total

1.  Sentinel node and breast cancer.

Authors:  N Beechey-Newman
Journal:  Eur J Surg Oncol       Date:  2004-04       Impact factor: 4.424

Review 2.  Anaphylactic response to blue dye during sentinel lymph node biopsy.

Authors:  Corinne Bézu; Charles Coutant; Anne Salengro; Emile Daraï; Roman Rouzier; Serge Uzan
Journal:  Surg Oncol       Date:  2010-11-11       Impact factor: 3.279

3.  Evaluation of the benefit of using blue dye in addition to radioisotope for sentinel lymph node biopsy in patients with breast cancer.

Authors:  Christine B Teal; Jennifer P Slocum; Esma A Akin
Journal:  Breast J       Date:  2005 Nov-Dec       Impact factor: 2.431

4.  Comparison of blue dye and isotope with blue dye alone in breast sentinel node biopsy.

Authors:  David B Y Syme; John P Collins; G Bruce Mann
Journal:  ANZ J Surg       Date:  2005-09       Impact factor: 1.872

Review 5.  Properties and characteristics of the dyes injected to assist axillary sentinel node localization in breast surgery.

Authors:  Y Masannat; H Shenoy; V Speirs; A Hanby; K Horgan
Journal:  Eur J Surg Oncol       Date:  2006-03-02       Impact factor: 4.424

Review 6.  A comparison of the adverse reactions associated with isosulfan blue versus methylene blue dye in sentinel lymph node biopsy for breast cancer.

Authors:  Sarmela Thevarajah; Tara L Huston; Rache M Simmons
Journal:  Am J Surg       Date:  2005-02       Impact factor: 2.565

7.  Sentinel node mapping affects intraoperative pulse oximetric recordings during breast cancer surgery.

Authors:  A-M Koivusalo; K Von Smitten; L Lindgren
Journal:  Acta Anaesthesiol Scand       Date:  2002-04       Impact factor: 2.105

8.  Adverse reactions to patent blue V dye - The NEW START and ALMANAC experience.

Authors:  L Barthelmes; A Goyal; R G Newcombe; F McNeill; R E Mansel
Journal:  Eur J Surg Oncol       Date:  2009-11-24       Impact factor: 4.424

9.  Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements.

Authors:  Sarah A McLaughlin; Mary J Wright; Katherine T Morris; Gladys L Giron; Michelle R Sampson; Julia P Brockway; Karen E Hurley; Elyn R Riedel; Kimberly J Van Zee
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544

10.  Why certain dyes are useful for localizing the sentinel lymph node.

Authors:  Chris Tsopelas; Richard Sutton
Journal:  J Nucl Med       Date:  2002-10       Impact factor: 10.057

View more
  5 in total

1.  Reassembly of 89 Zr-Labeled Cancer Cell Membranes into Multicompartment Membrane-Derived Liposomes for PET-Trackable Tumor-Targeted Theranostics.

Authors:  Bo Yu; Shreya Goel; Dalong Ni; Paul A Ellison; Cerise M Siamof; Dawei Jiang; Liang Cheng; Lei Kang; Faquan Yu; Zhuang Liu; Todd E Barnhart; Qianjun He; Han Zhang; Weibo Cai
Journal:  Adv Mater       Date:  2018-02-12       Impact factor: 30.849

2.  Validation of Contrast Enhanced Ultrasound Technique to Wire Localization of Sentinel Lymph Node in Patients with Early Breast Cancer.

Authors:  Maryam H Esfehani; Adel Yazdankhah-Kenari; Ramesh Omranipour; Habib Allah Mahmoudzadeh; Shahriar Shahriaran; Mohammad Reza Zafarghandi; Hadi Ahmadi Amoli
Journal:  Indian J Surg Oncol       Date:  2015-07-18

3.  Long-Term Outcome After Retro-Areolar Versus Peri-Tumoral Injection of Superparamagnetic Iron Oxide Nanoparticles (SPIO) for Sentinel Lymph Node Detection in Breast Cancer Surgery.

Authors:  Fredrik Wärnberg; Evelina Stigberg; Christine Obondo; Helena Olofsson; Shahin Abdsaleh; Madeleine Wärnberg; Andreas Karakatsanis
Journal:  Ann Surg Oncol       Date:  2019-03-04       Impact factor: 5.344

4.  A Randomized Prospective Non-Inferiority Trial of Sentinel Lymph Node Biopsy in Early Breast Cancer: Blue Dye Compared with Indocyanine Green Fluorescence Tracer.

Authors:  Michel Coibion; Fabrice Olivier; Audrey Courtois; Nathalie Maes; Véronique Jossa; Guy Jerusalem
Journal:  Cancers (Basel)       Date:  2022-02-10       Impact factor: 6.639

5.  Short-term and long-term outcomes of indocyanine green for sentinel lymph node biopsy in early-stage breast cancer.

Authors:  Bin Hua; Yao Li; Xin Yang; Xiaotian Ren; Xu Lu
Journal:  World J Surg Oncol       Date:  2022-08-09       Impact factor: 3.253

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.